Cardiovascular effects of increasing hemoglobin in chronic renal failure

American Journal of Nephrology

Volumn 16, Issue 4, 1996, Pages 263-267

  Mayer, Gert ^a   Horl W H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Blood pressure; Cardiac; Cardiac output; Clinical effects; Hypertrophy; Peripheral resistance; Recombinant human erythropoietin

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR EFFECT; CARDIOVASCULAR PERFORMANCE; CHRONIC KIDNEY FAILURE; HEALTH CARE COST; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEMATOCRIT; HEMODYNAMICS; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SHORT SURVEY; VASCULAR RESISTANCE;

EID: 0029989712     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000169007     Document Type: Article

References (40)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316:73-78.
2. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; ii: 1175-1178.
3. Van de Borne P, Ticlemans C, Vanherweghcm JL, Dcgaute JP: Effect of recombinant erythropoietin therapy on ambulatory blood pressure and heart rate in chronic haemodialysis patients. Nephrol Dial Transplant 1992;7:45-49.
4. Porter WB: Heart changes and physiologic adjustment in hookworm anaemia. Am Heart J 1937;13:550-555.
5. Neff MS, Kim KE, Persoff M, Onesti G, Swartz C: Hemodynamics of uremic anemia. Circulation 1971;63:876-883.
6. Williams B, Edmunds ME. Thompson JP. Burton PR. Feehallv J, Walls J: Does increasing haemoglobin concentration and hacmatocrit have a pressor effect in dialysis patients? Nephrol Dial Transplant 1989;4:787-791.
7. London GM. Zins B, Pannier B, Naret C. Bcr-thelot M, Jacquot C, Safar M, Drueke TB: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989;36:878-882.
8. Satoh K, Masuda T, Ikeda Y, Kurokawa S, Kamata K, Kikawada R, Takamoto T, Maru-mo F: Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients. Hypertension 1990;15:262-266.
9. Wirtz, JJ, Lcunissen KM, van Esser JW, Cher-iex EC, Slaaf DW, Reneman RS, van Hooff JP: Recombinant erythropoietin and its effects on macro- and microcirculation during normovolemia. A physiological study of hemodynamics, fluid status and skin microcirculation. Blood Purif 1990;8:285-294.
10. Mayer G, Cada M. Watzinger U, Barnas U, Graf H: Hemodynamic effects of partial correction of chronic anemia by recombinant human erythropoietin in patients on dialysis. Am J Kidney Dis 1991;17:286-289.
11. Tagawa H, Nagano M, Saito H, Umczu M, Yamakado M: Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin proposal for the hematocrit most beneficial to hcmodvnamics. Clin Neprol 1991;35:35-38.
12. Terucl JL, Pascual J, Jimenez M, Liano F, Rivera M, Martinez J, Ortuno J: Hemodynamic changes in hemodialysed patients during treatment with recombinant human erythropoietin. Nephron 1991:58:135-137.
13. Kamata K, Marumo F, Onoyama K: Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erylhropietin. Jpn CircJ 1991:55:649-656.
14. Metra M, Canclla G, La Canna G, Guaini T, Sandrini M, Gaggiotti M, Movilli E, Dei Cas L: Improvement in exercise capacity after correction of anemia in patients with end stage renal failure. Am J Cardiol 1991;68:1060-1066.
15. Quarcllo F, Martina G, Beltrame G, Boero R, Fomeris G, Borca M, ladarola GM, Stramig-noni E, Maffei S, Piccoli G: Effects of erythropoietin on the cardiovascular system and the intradialytic behaviour. Minerva Urol Nefrol 1991;43:125-130.
16. Pascual J, Terucl JL. Marcen R. Liano F. Moya JL„ Jimenez M, Ortuno J: Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis. Int J Artif Organs 1992; 15: 349-353.
17. Martinez Vea A, Bardaji A, Garcia C, Ridao C, Richart C, Oliver JA: Long term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidney Dis 1992; 19:353-357.
18. Fellner SK, Lang RM. Neumann A. Korcarz.C, Borow KM: Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 1993:44:1309-1315.
19. Cropp GJA: Hemodynamic responses to oxygen breathing in children with severe anemia. Circulation 1959:15:493-500.
20. Roger SD, Grastv MS. Baker LR, Raine AE: Effects of oxygen breathing and erythropoietin on hypoxic vasodilatation in uremic anaemia. Kidney Int 1992;42:975-980.
21. Mayer G, Stclfenelli Th, Cada EM, Thum J, Stummvoll HK, Graf H: Blood viscosity and hemodynamic parameter in dialysis patients treated with human recombinat erythropoietin. Lancet 1988;i:358-359.
22. Müller R. Steffen HM, Brunner R, Saric J, Pol-lok M, Baldamus CA, Kaufmann W: Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin therapy for renal anemia. Clin Invest Med 1991:14:614-622.
23. Heidenreich S. Rah K. Zidek W: Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991:39:259-265.
24. Neusser M, Tepci M, Zidek W: Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 1993;27:1233-1236.
25. Tsukuda H, Ishimitsu T, Ogawa Y, Sugimoto T, Yagi S: Direct vasopressor effects of erythropoietin in genetically hypertensive rats. Life Sei 1993;52:1425-1434.
26. Cirillo M, Laurcnzi M, Trcvisan M, Stamler J: Hematocrit, blood pressure and hypertension. The Gubbio Population Study. Hypertension 1992;20:319-326.
27. Raine AG, Roger SD: Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18(suppl I):76-83.
28. Fernandez A, Vega N, Jimenez F, Macia M, Laraudiogoitia E, Hortal L. Perdomo M, Plaza C, Rodriguez JC, Palop L: Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Nephrol 1992;12:204-211.
29. Onoyama K, Kumagai H, Takeda K, Shima-matsu K, Fujishima M: Effects of human recombinant erythropoietin on anaemia, systemic haemodynamics and renal function in predialysis renal failure patients. Nephrol Dial Transplant 1989;4:966-970.
30. Graf H, Bamas U, for the Austrian Multicenter Study Group of r-huEPO in Predialysis Patients: Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 1992;61:399-403.
31. National Institute of Diabetes and Digestive and Kidney Disease: US Renal Data System Annual Report. Bethesda. National Institutes of Health, 1990.
32. Silberbcg JS, Barre PE, Prichard SS, Snider-rnan AD: Impact of left ventricular hypertrophy on survival in end stage renal disease. Kidney Int 1989;36:286-291.
33. Pascual J, Teruel JL, Moya IL, Liano F, Jinten-ez-Mena M, Ortuno J: Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on dialysis. Clin Nephrol 1991;35:280-286.
34. Macdougall IC, Lewis NP, Saunders MJ: Long term cardiorespiratory effects of amelioration of anemia by erythropoietin. Lancet 1990:335: 489.
35. Wizemann V, Kaufmann J, Krantcr W: Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992:62: 161-165.
36. Nonnast-Danicl B, Crcutzig A, Kuhn J, Bahl-mann J, Reimers E, Brunkhorst H, Gaspary I, Koch DM: Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation; in Koch KM, Kühn K, Nonnast-Daniel B, Seigalla P (eds): Treatment of Renal Anemia with Recombinant Human Erythropoietin. Contr Nephrol. Basel, Karger, 1988, vol 66, pp 185-194.
37. Johnson VVJ, McCarthy JT, Takehiko Y, Os-mundson PJ, Ilstrup DM, Janson BM, Bowie EJ: Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability. Kidney Int 1990:38: 919-924.
38. Eschbach JW. Aquiling T, Haley NR, Fan MH, Blagg CR: The long term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 1992;38(suppl 1):98-103.
39. Powe NR, Griffiths R, Bass EB: Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end stage renal disease. J Am Soc Nephrol 1993;3:1660-1671.
40. Powc NR, Griffiths R, Watson AJ. Anderson GF, de Lissovoy G, Greer JW, Herbert RJ, Milam RA, Whelton PK: Effect of recombinant erythropoietin on hospital admissions, réadmissions, length of stay and costs of dialysis patients. J Am Soc Nephrol 1994:4:1455-1465